## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($56.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Canada clears at-home injection for rare, painful FCS disorder**
- Source: Stock Titan | 20260105T123253 | Bullish | Relevance: 100%
- Health Canada has approved REDEMPLOâ„¢ (plozasiran) for the at-home treatment of Familial Chylomicronemia Syndrome (FCS), a rare condition causing extremely high triglyceride levels and acute pancreatitis risk. Developed by Arrowhead Pharmaceuticals, REDEMPLO is the first and only siRNA medicine approved for FCS in Canada, allowing self-administration every three months. This approval marks a significant advancement for Canadian patients with limited treatment options.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($0.22M) |
| Sells | 11 ($12.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-7.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $12M sold (11 transactions in 90 days).
3. Elevated short interest (9.8%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 3 raises (avg +42%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -34% YoY, concerning. Analyst sentiment positive (3 raises, avg +42%, $72 target (+12%)). Insider selling cluster ($12.3M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.8B |
| Beta | 1.22 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 1.4% to -6.2% (-7.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.2pp (needs >3.0% for momentum thesis). Underperforming sector by 6.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 2.25x) but short-term weakness (below SMA20). MACD histogram bearish (-1.36), momentum weakening. RSI neutral at 52. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.23% (CS: 1) | Weak |
| RSI_14 | 51.9 | Neutral |
| MACD Histogram | -1.36 | Bearish |
| vs SMA20 | 0.943x | Below |
| vs SMA50 | 1.192x | Above |
| vs SMA200 | 2.250x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $63.88
- **Stop Loss:** $56.40 (11.7% risk)
- **Target:** $71.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 115
- **Position Value:** $7,346.20
- **Portfolio %:** 7.35%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*